Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D.

Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.

PMID:
30472651
2.

Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses.

Pitoiset F, Cassard L, El Soufi K, Boselli L, Grivel J, Roux A, Klatzmann D, Chaput N, Rosenzwajg M.

Cytometry A. 2018 Aug;93(8):793-802. doi: 10.1002/cyto.a.23570. Epub 2018 Aug 31.

PMID:
30168890
3.

Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol.

Lorenzon R, Mariotti-Ferrandiz E, Aheng C, Ribet C, Toumi F, Pitoiset F, Chaara W, Derian N, Johanet C, Drakos I, Harris S, Amselem S, Berenbaum F, Benveniste O, Bodaghi B, Cacoub P, Grateau G, Amouyal C, Hartemann A, Saadoun D, Sellam J, Seksik P, Sokol H, Salem JE, Vicaut E, Six A, Rosenzwajg M, Bernard C, Klatzmann D.

BMJ Open. 2018 Aug 30;8(8):e021037. doi: 10.1136/bmjopen-2017-021037.

4.

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2.

Churlaud G, Abbara C, Vinot PA, Fourcade G, Ritvo PG, Lorenzon R, Rosenzwajg M, Diquet B, Klatzmann D.

J Allergy Clin Immunol. 2018 Oct;142(4):1344-1346.e3. doi: 10.1016/j.jaci.2018.06.006. Epub 2018 Jun 18. No abstract available.

5.

IL-2 antibodies in type 1 diabetes and during IL-2 therapy.

Churlaud G, Rosenzwajg M, Cacoub P, Saadoun D, Valteau-Couanet D, Chaput N, Pugliese A, Klatzmann D.

Diabetologia. 2018 Sep;61(9):2066-2068. doi: 10.1007/s00125-018-4649-4. Epub 2018 Jun 2. No abstract available.

PMID:
29860627
6.

A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials.

Pitoiset F, Barbié M, Monneret G, Braudeau C, Pochard P, Pellegrin I, Trauet J, Labalette M, Klatzmann D, Rosenzwajg M.

Cytometry B Clin Cytom. 2018 Sep;94(5):621-626. doi: 10.1002/cyto.b.21622. Epub 2018 Jan 23.

PMID:
29316248
7.

B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.

Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P.

Kidney Int. 2017 Jul;92(1):227-237. doi: 10.1016/j.kint.2017.01.012. Epub 2017 Mar 15.

PMID:
28318628
8.

Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.

Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, Le Garff-Tavernier M, Si Ahmed SN, Alric L, Fontaine H, Bellier B, Maciejewski A, Rosenzwajg M, Klatzmann D, Musset L, Poynard T, Cacoub P, Saadoun D.

Gastroenterology. 2017 Jun;152(8):2052-2062.e2. doi: 10.1053/j.gastro.2017.02.037. Epub 2017 Mar 6.

PMID:
28274850
9.

Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells.

Lecendreux M, Churlaud G, Pitoiset F, Regnault A, Tran TA, Liblau R, Klatzmann D, Rosenzwajg M.

PLoS One. 2017 Jan 20;12(1):e0169836. doi: 10.1371/journal.pone.0169836. eCollection 2017.

10.

Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.

Trébéden-Negre H, Vieillard V, Rosenzwajg M, Garderet L, Cherai M, Nguyen-Quoc S, Tanguy ML, Norol F.

Bone Marrow Transplant. 2017 Mar;52(3):480-483. doi: 10.1038/bmt.2016.311. Epub 2016 Dec 12. No abstract available.

PMID:
27941770
11.

A possible role for IL-17 in Clarkson's disease.

Simonin M, Corbeau P, Durand P, Rosenzwajg M, Filleron A, Tran TA.

Eur J Paediatr Neurol. 2016 Nov;20(6):953-956. doi: 10.1016/j.ejpn.2016.08.003. Epub 2016 Aug 15.

PMID:
27601291
12.

Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice.

Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):324-36. doi: 10.1164/rccm.201410-1765OC.

13.

Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy.

Churlaud G, Pitoiset F, Jebbawi F, Lorenzon R, Bellier B, Rosenzwajg M, Klatzmann D.

Front Immunol. 2015 Apr 15;6:171. doi: 10.3389/fimmu.2015.00171. eCollection 2015.

14.

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D.

J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.

15.

Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.

Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, Terrier B, Geri G, Rosenzwajg M, Klatzmann D, Fourret P, Cluzel P, Chiche L, Gaudric J, Koskas F, Cacoub P.

Arthritis Rheumatol. 2015 May;67(5):1353-60. doi: 10.1002/art.39037.

16.

Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.

Yu A, Snowhite I, Vendrame F, Rosenzwajg M, Klatzmann D, Pugliese A, Malek TR.

Diabetes. 2015 Jun;64(6):2172-83. doi: 10.2337/db14-1322. Epub 2015 Jan 9.

17.

Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.

Rosenzwajg M, Churlaud G, Hartemann A, Klatzmann D.

Curr Diab Rep. 2014 Dec;14(12):553. doi: 10.1007/s11892-014-0553-6. Review.

PMID:
25344788
18.

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy.

Van Gool F, Molofsky AB, Morar MM, Rosenzwajg M, Liang HE, Klatzmann D, Locksley RM, Bluestone JA.

Blood. 2014 Dec 4;124(24):3572-6. doi: 10.1182/blood-2014-07-587493. Epub 2014 Oct 16.

19.

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, Cabanne L, Churlaud G, Suarez F, Socié G, Gregoire L, Debbache K, Bernard C, Beaumont JL, Azar N, Boyer O, Roudot-Thoraval F, Cohen JL, Cordonnier C, Lemoine FM, Klatzmann D.

Leukemia. 2014 Dec;28(12):2406-10. doi: 10.1038/leu.2014.237. Epub 2014 Aug 8. No abstract available.

PMID:
25102947
20.

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.

PMID:
24622415
21.

Th1 response and systemic treg deficiency in inclusion body myositis.

Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, Wanschitz J, Musset L, Charuel JL, Eymard B, Salomon B, Duyckaerts C, Maisonobe T, Dubourg O, Herson S, Klatzmann D, Benveniste O.

PLoS One. 2014 Mar 4;9(3):e88788. doi: 10.1371/journal.pone.0088788. eCollection 2014.

22.

CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis.

Terrier B, Nagata S, Ise T, Rosenzwajg M, Pastan I, Klatzmann D, Saadoun D, Cacoub P.

Arthritis Rheumatol. 2014 Feb;66(2):433-43. doi: 10.1002/art.38222.

23.

Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection.

Terrier B, Chaara W, Dufat L, Geri G, Rosenzwajg M, Musset L, Sène D, Saadoun D, Six A, Klatzmann D, Cacoub P.

Autoimmun Rev. 2014 Mar;13(3):319-26. doi: 10.1016/j.autrev.2013.11.001. Epub 2013 Nov 9. Review.

PMID:
24220267
24.

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR+ NK cell levels correlate with disease outcome.

Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le Cesne A, Soria JC, Paci A, Rosenzwajg M, Klatzmann D, Eggermont A, Robert C, Zitvogel L.

Oncoimmunology. 2013 Feb 1;2(2):e23080.

25.

Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I, Joly F, Rosenzwajg M, Sene D, Benech P, Musset L, Klatzmann D, Meffre E, Cacoub P.

Arthritis Rheum. 2013 Apr;65(4):1085-96. doi: 10.1002/art.37828.

26.

Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation.

Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L, Piette JC, Six A, Klatzmann D, Saadoun D, Patrice C, Costedoat-Chalumeau N.

Arthritis Res Ther. 2012 Oct 17;14(5):R221. doi: 10.1186/ar4060.

27.

Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.

Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzwajg M, Musset L, Klatzmann D, Saadoun D, Cacoub P.

J Rheumatol. 2012 Sep;39(9):1819-28. doi: 10.3899/jrheum.120468. Epub 2012 Aug 1.

PMID:
22859347
28.

Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy.

Touil S, Rosenzwajg M, Landau DA, Le Corvoisier P, Frédéric C, Klatzmann D, Maury S, Cohen JL.

Haematologica. 2012 Nov;97(11):1678-85. doi: 10.3324/haematol.2011.056374. Epub 2012 May 11.

29.

Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis.

Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, Fouret P, Musset L, Benveniste O, Six A, Klatzmann D, Saadoun D, Cacoub P.

Arthritis Rheum. 2012 Jun;64(6):2001-11. doi: 10.1002/art.34327. Epub 2011 Dec 6.

30.

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D.

N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

31.

Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity.

Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, Garrido M, Ghillani-Dalbin P, Klatzmann D, Cacoub P, Saadoun D.

J Immunol. 2011 Dec 15;187(12):6550-63. doi: 10.4049/jimmunol.1102022. Epub 2011 Nov 14.

32.

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, Klatzmann D, Cacoub P, Saadoun D.

J Allergy Clin Immunol. 2011 Sep;128(3):655-64. doi: 10.1016/j.jaci.2011.05.029. Epub 2011 Jul 2.

PMID:
21724243
33.

Systemic diseases: from amyloidosis to cryoglobulinemia.

Grünfeld JP.

Clin J Am Soc Nephrol. 2010 Nov;5(11):1912-5. doi: 10.2215/CJN.08130910. Epub 2010 Oct 14. No abstract available.

34.

Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome.

Terrier B, Bièche I, Maisonobe T, Laurendeau I, Rosenzwajg M, Kahn JE, Diemert MC, Musset L, Vidaud M, Sène D, Costedoat-Chalumeau N, Le Thi-Huong D, Amoura Z, Klatzmann D, Cacoub P, Saadoun D.

Blood. 2010 Nov 25;116(22):4523-31. doi: 10.1182/blood-2010-02-267542. Epub 2010 Aug 20.

35.

Regulatory T cell content in the bone marrow graft does not predict the occurrence of acute GVHD.

Rosenzwajg M, Dhédin N, Maury S, Bensimon G, Landau DA, Norol F, Trébéden-Negre H, Uzunov M, Vernant JP, Klatzmann D, Cohen JL.

Biol Blood Marrow Transplant. 2011 Feb;17(2):265-9. doi: 10.1016/j.bbmt.2010.07.024. Epub 2010 Aug 5.

36.

[Quality control of defrosted cord blood units: results from an inter-laboratory study].

Panterne B, Richard MJ, Sabatini C, Pouthier F, Mouillot L, Bardey D, Boulanger F, Créa S, Dal Cortivo L, Decot V, Fleury-Cappellesso S, Giraud C, Lapierre V, Léauté AG, Le Berre C, Lemarié C, Piard N, Rapatel C, Rosenzwajg M.

Transfus Clin Biol. 2010 Apr;17(2):41-6. doi: 10.1016/j.tracli.2010.06.006. Epub 2010 Jul 31. French.

PMID:
20674441
37.

CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.

Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL.

Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302.

38.

Delayed recovery after autologous peripheral hematopoietic cell transplantation: potential effect of a high number of total nucleated cells in the graft.

Trébéden-Negre H, Rosenzwajg M, Tanguy ML, Lefrere F, Azar N, Heshmati F, Belhocine R, Vernant JP, Klatzmann D, Norol F.

Transfusion. 2010 Dec;50(12):2649-59. doi: 10.1111/j.1537-2995.2010.02746.x.

PMID:
20576009
39.

Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppéré B, Blanc F, Musset L, Piette JC, Rosenzwajg M, Cacoub P.

Blood. 2010 Jul 22;116(3):326-34; quiz 504-5. doi: 10.1182/blood-2009-10-248518. Epub 2010 May 3.

40.

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.

Terrier B, Saadoun D, Sène D, Sellam J, Pérard L, Coppéré B, Karras A, Blanc F, Buchler M, Plaisier E, Ghillani P, Rosenzwajg M, Cacoub P.

Arthritis Rheum. 2009 Aug;60(8):2531-40. doi: 10.1002/art.24703.

41.

Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.

Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, Chaput N, Barrou B, Thioun N, Gattegnio B, Selles F, Six A, Azar N, Lotz JP, Buzyn A, Sibony M, Delcourt A, Boyer O, Herson S, Klatzmann D, Lacave R.

Int J Oncol. 2009 Sep;35(3):569-81.

PMID:
19639177
42.

Clinical grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene: authors' reponse.

Guillot-Delost M, Cheraï M, Hamel Y, Rosenzwajg M, Baillou C, Simonin G, Leclercq V, Mariotti-Ferrandiz ME, Six A, Bon-Durand V, Maury S, Salomon BL, Cohen JL, Klatzmann D, Lemoine FM.

J Gene Med. 2009 Aug;11(8):737-8. doi: 10.1002/jgm.1358. No abstract available.

PMID:
19514009
43.

IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment.

Bento CA, Hygino J, Andrade RM, Saramago CS, Silva RG, Silva AA, Linhares UC, Brindeiro R, Tanuri A, Rosenzwajg M, Klatzmann D, Andrade AF.

AIDS. 2009 Jan 2;23(1):9-18. doi: 10.1097/QAD.0b013e328317461e.

PMID:
19050381
44.

Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J.

Gut. 2009 Apr;58(4):520-9. doi: 10.1136/gut.2008.158824. Epub 2008 Nov 20.

PMID:
19022917
45.

Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.

Landau DA, Rosenzwajg M, Saadoun D, Trébeden-Negre H, Klatzmann D, Cacoub P.

Arthritis Rheum. 2008 Sep;58(9):2897-907. doi: 10.1002/art.23759.

46.

Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene.

Guillot-Delost M, Cheraï M, Hamel Y, Rosenzwajg M, Baillou C, Simonin G, Leclercq V, Mariotti-Ferrandiz ME, Six A, Bon-Durand V, Maury S, Salomon BL, Cohen JL, Klatzmann D, Lemoine FM.

J Gene Med. 2008 Aug;10(8):834-46. doi: 10.1002/jgm.1220.

PMID:
18615770
47.

The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.

Landau DA, Rosenzwajg M, Saadoun D, Klatzmann D, Cacoub P.

Ann Rheum Dis. 2009 Mar;68(3):337-44. doi: 10.1136/ard.2007.085910. Epub 2008 Apr 23.

PMID:
18434450
48.

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P.

Blood. 2008 Jun 1;111(11):5334-41. doi: 10.1182/blood-2007-11-122713. Epub 2008 Feb 21.

49.

Small intestinal CD4+ T-cell lymphoma: a rare distinctive clinicopathological entity associated with prolonged survival.

Svrcek M, Garderet L, Sebbagh V, Rosenzwajg M, Parc Y, Lagrange M, Bennis M, Lavergne-Slove A, Fléjou JF, Fabiani B.

Virchows Arch. 2007 Dec;451(6):1091-3. Epub 2007 Aug 3. No abstract available.

PMID:
17676338
50.

Supplemental Content

Loading ...
Support Center